SSG
CHRS icon

Summit Securities Group’s Coherus Oncology CHRS Stock Holding History

Summit Securities Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100
Closed -$2K – 303
2015
Q3 		$2K Buy
+100
New +$3.04K ﹤0.01% 306

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Summit Securities Group's CHRS Position: Q4 2015 in Review

Summit Securities Group sold out of Coherus Oncology (CHRS) in Q4 2015, closing a stake of 100 shares — an estimated $2K sold.

Summit Securities Group first reported a position in CHRS in Q3 2015 and held it in 1 quarter. The position peaked at $2K in Q3 2015. 77 funds tracked by Wall St. Rank hold CHRS as of Q4 2015.

  • Summit Securities Group reported no remaining Coherus Oncology position as of Q4 2015 after selling out during the quarter.
  • Summit Securities Group sold 100 Coherus Oncology shares in Q4 2015, an estimated $2K.
  • Summit Securities Group first reported a position in Coherus Oncology in Q3 2015 and held it in 1 quarter.
  • Summit Securities Group's Coherus Oncology position peaked at $2K in Q3 2015.
  • 77 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2015.

Based on Summit Securities Group's 13F filing for Q4 2015, filed 11 Feb 2016.